(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ONEGENE PROGRAM

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

ONEGENE PROGRAM

ST13

US500000090695869

Class

35, 36

Filing

90695869

Registration

7270239

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

32

Latest update

01/09/2024

Trademark type

Combined

Nice classes

35, 36

Filing date

05/07/2021

Registration date

01/09/2024

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/09/2024

Last transaction

01/09/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

05/06/2021

First use in commerce

05/06/2021

Drawing code

5

Owner type

99

Owner location

Basel, CH

Examiner

SALCIDO, JOHN CHARLES

Law office

N40

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the word "ONEGENE" with the word "ONE" in dark blue followed by and the word "GENE" in light blue above the word "PROGRAM" in gray.

Holders and representatives

Holders

Novartis AG

Representatives

Maury M. Tepper, III TEPPER & EYSTER, PLLC

Technical classification

Nice Classes

Class 35Class 36

Vienna Codes

No Vienna codes available.

Goods and services

Class 35

Business administration of a patient assistance program for providing prescription drugs at reduced cost

Class 36

Providing information regarding insurance coverage and reimbursement for prescription drugs; financial administration of a patient assistance program for providing prescription drugs at reduced cost

Publications

History of USPTO decisions and trademark events.

32 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

01/09/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

01/09/2024

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

12/02/2023

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

12/01/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/28/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/28/2023

ALIE

ASSIGNED TO LIE

11/28/2023

DOCK

ASSIGNED TO EXAMINER

11/07/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

06/23/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

05/23/2023

GNRT

NON-FINAL ACTION E-MAILED

05/23/2023

CNRT

SU - NON-FINAL ACTION - WRITTEN

05/23/2023

SUPC

STATEMENT OF USE PROCESSING COMPLETE

05/02/2023

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

05/01/2023

IUAF

USE AMENDMENT FILED

04/12/2023

EISU

TEAS STATEMENT OF USE RECEIVED

04/12/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

10/06/2022

EX1G

SOU EXTENSION 1 GRANTED

10/04/2022

EXT1

SOU EXTENSION 1 FILED

10/04/2022

EEXT

SOU TEAS EXTENSION RECEIVED

10/04/2022

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

04/19/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/22/2022

PUBO

PUBLISHED FOR OPPOSITION

02/22/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

02/02/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

01/18/2022

XAEC

EXAMINER'S AMENDMENT ENTERED

01/18/2022

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

01/18/2022

GNEA

EXAMINERS AMENDMENT E-MAILED

01/18/2022

CNEA

EXAMINERS AMENDMENT -WRITTEN

01/18/2022

DOCK

ASSIGNED TO EXAMINER

01/12/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/09/2021

NWAP

NEW APPLICATION ENTERED

05/11/2021

Continuous trademark protection

Get notified about every new filing that threatens ONEGENE PROGRAM or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.